Aldeyra Therapeutics, Inc.
http://www.aldeyra.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aldeyra Therapeutics, Inc.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
OKYO Hits Multiple Dry Eye Endpoints, Plans Move Into Phase III
OKYO’s eye drop OK-101 has hit endpoints for ocular pain, tear film breakup time and conjunctival staining in Phase II, while demonstrating a placebo-like tolerability profile.
Sylentis Piles On Another Failure In Dry Eye
The PharmaMar subsidiary is the latest group to crash in a notoriously hard-to-treat disease, leaving Bausch + Lomb more firmly in command of the field.
Aldeyra’s Claimed Success In Dermatitis Looks Premature
The group claims a Phase II hit with ADX-629, but the eight-patient open-label study has in fact proved little but point to future possibilities.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Aldexa Therapeutics, Inc.
- Helio Vision, Inc.
- Neuron Systems, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice